Short Interest in Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACCU) Decreases By 33.7%

Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACCU) saw a large drop in short interest in the month of December. As of December 31st, there was short interest totaling 2,161 shares, a drop of 33.7% from the December 15th total of 3,261 shares. Based on an average daily trading volume, of 341 shares, the short-interest ratio is presently 6.3 days. Based on an average daily trading volume, of 341 shares, the short-interest ratio is presently 6.3 days.

Hedge Funds Weigh In On Oaktree Acquisition Corp. III Life Sciences

A hedge fund recently bought a new stake in Oaktree Acquisition Corp. III Life Sciences stock. Clear Street Group Inc. purchased a new stake in shares of Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACCU) in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 20,333 shares of the company’s stock, valued at approximately $217,000.

Oaktree Acquisition Corp. III Life Sciences Stock Down 1.5%

OACCU stock traded down $0.17 during trading on Friday, reaching $10.64. 254 shares of the stock were exchanged, compared to its average volume of 4,151. The firm’s 50 day moving average is $10.76 and its 200 day moving average is $10.74. Oaktree Acquisition Corp. III Life Sciences has a twelve month low of $10.12 and a twelve month high of $11.06.

Oaktree Acquisition Corp. III Life Sciences Company Profile

Oaktree Acquisition Corp. III Life Sciences (NASDAQ: OACCU) is a special purpose acquisition company formed to target businesses in the life sciences sector. As a blank‐check vehicle, the company raises capital through an initial public offering with the purpose of acquiring or merging with one or more operating companies. Its focus areas include biotechnology, pharmaceuticals, medical devices and healthcare services.

Established in Delaware and sponsored by affiliates of Oaktree Capital Management, OACCU leverages the resources and investment expertise of one of the world’s leading alternative asset managers.